Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, contro... - PubMed - NCBI

Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, contro... - PubMed - NCBI

Genet Med. 2016 Sep 1. doi: 10.1038/gim.2016.108. [Epub ahead of print]

Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial.

Metcalfe KA1,2, Dennis CL1,2, Poll A1, Armel S3, Demsky R3, Carlsson L2, Nanda S1, Kiss A4, Narod SA1.

Author information

Abstract

PURPOSE:

Women with a BRCA1 or BRCA2 mutation are at high risk for breast cancer and must make important decisions about breast cancer prevention and screening. In the current study, we report a multisite, randomized, controlled trial evaluating the effectiveness of a decision aid for breast cancer prevention in women with a BRCA mutation with no previous diagnosis of cancer.

METHODS:

Within 1 month of receiving a positive BRCA result, women were randomized to receive either usual care (control group) or decision aid (intervention group). Participants were followed at 3, 6, and 12 months; were asked about preventive measures; and completed standardized questionnaires assessing decision making and psychosocial functioning.

RESULTS:

One hundred fifty women were randomized. Mean cancer-related distress scores were significantly lower in the intervention group compared with the control group at 6 months (P = 0.01) and at 12 months postrandomization (P = 0.05). Decisional conflict scores declined over time for both groups and at no time were there statistical differences between the two groups.

CONCLUSION:

The decision aid for breast cancer prevention in women with a BRCA1 or BRCA2 mutation is effective in significantly decreasing cancer-related distress within the year following receipt of positive genetic test results.Genet Med advance online publication 01 September 2016Genetics in Medicine (2016); doi:10.1038/gim.2016.108.

PMID:

 

27584910

 

DOI:

 

10.1038/gim.2016.108

[PubMed - as supplied by publisher]

Public Health Genomics Knowledge Base (v1.2)






Last Updated: Sep 08, 2016

• BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
  Chun Danielle S et al. Familial cancer 2016 Sep
• Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial.
  Metcalfe Kelly A et al. Genetics in medicine : official journal of the American College of Medical Genetics 2016 Sep
• Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
  Morse Christopher B, et al. Gynecologic oncology 2016 8
• BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype.
  Al-Shamsi Humaid O, et al. Journal of gastrointestinal oncology 2016 8 (4) 556-61
• Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?
  Larouche Geneviève et al. Familial cancer 2016 Aug
• Next-Generation Sequencing of Tumors to Better Estimate the Clinical Significance of Non-BRCA Germline Deleterious Mutations.
  Sorscher Steven M, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 8
• BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety.
  Printz Carrie et al. Cancer 2016 Apr 122(8) 1149
• Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon?
  Agranat Sivan et al. The breast journal 2016 Aug
• Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial.
  Kiechle Marion et al. Trials 2016 17368
• Evolution of Hereditary Breast Cancer Genetic Services: Are Changes Reflected in the Knowledge and Clinical Practices of Florida Providers?
  Cragun Deborah et al. Genetic testing and molecular biomarkers 2016 Aug
• Finding all BRCA pathogenic mutation carriers: best practice models.
  Hoogerbrugge Nicoline et al. European journal of human genetics : EJHG 2016 Sep 24 Suppl 1S19-26
• How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
  Watts Kaaren J et al. BMC cancer 2012 12320
• New challenges for BRCA testing: a view from the diagnostic laboratory.
  Wallace Andrew J et al. European journal of human genetics : EJHG 2016 Sep 24 Suppl 1S10-8
• Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk.
  Giordano Sara, et al. Journal of adolescent and young adult oncology 2016 8
• Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.
  Flores Kristina G et al. Journal of genetic counseling 2016 Aug

• CDC Information (4)
• CDC-Authored Pub (2)

• Human (45)
• Pathogen (0)

• Human (477)
• Pathogen (0)

• Human (140)
• Pathogen (0)

• Guidelines (7)
• Tier Table (3)
• Synthesis (7)

• Huamn (27)
• Pathogen (0)

Relevant Resources

• Cancer Genomics and Epidemiology Navigator (CGEN)
• Genetics and Genomics Competencies Center (G2C2)
• NIH Genetic Testing Registry
• NIH MedGen Database
• Online Mendelian Inheritance in Man (OMIM)
• PharmGKB